Amarin Corp Plc (AMRN)

[Sam81]

"As of the date of this report, we had 47 patent applications in the United States that have been either issued or allowed and more than 30
additional patent applications are pending in the United States. Such 47 allowed and issued applications include the following:
• 2 issued U.S. patents directed to a pharmaceutical composition of Vascepa in a capsule that have terms that expire in 2020 and 2030,
respectively,
• 1 issued U.S. patent covering a composition containing highly pure EPA that expires in 2021,
• 36 U.S. patents covering the use of Vascepa in either the MARINE or anticipated ANCHOR indication that have terms that expire in 2030,
• 3 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the ANCHOR patient population with a term that expires in 2030,
• 2 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the MARINE patient population with a term that expires in 2030,
• 1 additional patent related to a pharmaceutical composition comprised of free fatty acids and uses thereof to treat both the MARINE and ANCHOR patient populations with a term that expires in 2030,
• 1 additional patent related to a formulation of EPA/DHA and uses thereof with a term that expires in 2030, and
• 1 additional patent related to the use of Vascepa to treat obesity with a term that expires in 2030."

10K